Trial Profile
A Randomized, Controlled, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Breast Cancer and Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in the Treatment of HER2-positive Advanced Breast With Liver Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Disitamab vedotin (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer; HER2 positive breast cancer; Liver metastases; Male breast cancer
- Focus Therapeutic Use
- Sponsors RemeGen
- 18 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Jul 2024.
- 23 Nov 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 23 Nov 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.